NEW CRYSTALLINE FORMS OF N-(3-(2-(2-HYDROXYETHOXY)-6-MORPHOLINOPYRIDIN-4-YL)-4-METHVLPHENYL)-2 (TRIFLUOROMETHYL)ISONICOTINAMIDE AS RAF INHIBITORS FOR THE TREATMENT OF CANCER

NEW CRYSTALLINE FORMS OF N-(3-(2-(2-HYDROXYETHOXY)-6-MORPHOLINOPYRIDIN-4-YL)-4-METHVLPHENYL)-2 (TRIFLUOROMETHYL)ISONICOTINAMIDE AS RAF INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LI, ZAIXING, WAYKOLE, LILADHAR MURLIDHAR, HARLACHER, CORNELIUS STEPHEN
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers. La présente invention concerne des formes cristallines de N-(3-(2-(2-hydroxyéthoxy)-6-morpholinopyridin-4-yl)-4-méthylphényl)-2-(trifluorométhyl)isonicotinamide et des procédés de préparation correspondants. En outre, l'invention concerne une composition pharmaceutique comprenant lesdites formes cristallines de N-(3-(2-hydroxyéthoxy)-6-morpholinopyridin-4-yl)-4-méthylphényl)-2-(trifluorométhyl)isonicotinamide, et au moins un excipient pharmaceutiquement acceptable. La composition pharmaceutique selon la présente invention peut être utilisée en tant que médicament, en particulier pour le traitement du cancer.